A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Sponsor: Eli Lilly and Company
Terminated
Study was terminated due to enrollment futility.
Listed as NCT03742973, this PHASE2 trial focuses on Primary Biliary Cholangitis and remains terminated or withdrawn. Sponsored by Eli Lilly and Company, it has been updated 19 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
19 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 14 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Nov 2019 — Nov 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .